Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis

• Published in: Allergy 2006-11, Vol.61 (11), p.1319-1325
• Main Authors: Barnes, M. L., Biallosterski, B. T., Fujihara, S., Gray, R. D., Fardon, T. C., Lipworth, B. J.
• Format: Article
• Language: English
• Subjects: adenosine monophosphate; Adenosine Monophosphate - administration & dosage; Administration, Intranasal; Adolescent; Anti-Allergic Agents - administration & dosage; Anti-Allergic Agents - adverse effects; Double-Blind Method; Female; Humans; Male; Mometasone Furoate; Nasal Provocation Tests; peak nasal inspiratory flow; persistent allergic rhinitis; Pregnadienediols - administration & dosage; Pregnadienediols - adverse effects; Rhinitis, Allergic, Perennial - diagnosis; Rhinitis, Allergic, Perennial - drug therapy; Treatment Outcome
• ISSN: 0105-4538; 1398-9995; 0108-1675
• DOI: 10.1111/j.1398-9995.2006.01165.x

Background:  Response to a single dose nasal adenosine monophosphate challenge has been used as a surrogate inflammatory marker for allergic rhinitis. Attenuation of response following intranasal corticosteroid would further validate the challenge. Objective:  To assess the effect of 4 weeks of 200 mcg once daily mometasone furoate nasal spray on a simplified (single 160 mg dose) nasal adenosine monophosphate challenge. Methods:  Twenty participants with persistent allergic rhinitis completed a double blind placebo‐controlled crossover study. Outcome measures were the peak nasal inspiratory flow and total nasal symptoms score responses to nasal adenosine monophosphate challenge, as well as domiciliary peak nasal inspiratory flow and patient symptom diary cards. Results:  Mometasone significantly (P